Literature DB >> 34523888

Neglected Parasitic Infections: What Family Physicians Need to Know-A CDC Update.

Paul T Cantey1, Susan P Montgomery1, Anne Straily1.   

Abstract

Chagas disease, cysticercosis, and toxoplasmosis affect millions of people in the United States and are considered neglected parasitic diseases. Few resources are devoted to their surveillance, prevention, and treatment. Chagas disease, transmitted by kissing bugs, primarily affects people who have lived in Mexico, Central America, and South America, and it can cause heart disease and death if not treated. Chagas disease is diagnosed by detecting the parasite in blood or by serology, depending on the phase of disease. Antiparasitic treatment is indicated for most patients with acute disease. Treatment for chronic disease is recommended for people younger than 18 years and generally recommended for adults younger than 50 years. Treatment decisions should be individualized for all other patients. Cysticercosis can manifest in muscles, the eyes, and most critically in the brain (neurocysticercosis). Neurocysticercosis accounts for 2.1% of all emergency department visits for seizures in the United States. Diagnosing neurocysticercosis involves serology and neuroimaging. Treatment includes symptom control and antiparasitic therapy. Toxoplasmosis is estimated to affect 11% of people older than six years in the United States. It can be acquired by ingesting food or water that has been contaminated by cat feces; it can also be acquired by eating undercooked, contaminated meat. Toxoplasma infection is usually asymptomatic; however, people who are immunosuppressed can develop more severe neurologic symptoms. Congenital infection can result in miscarriage or adverse fetal effects. Diagnosis is made with serologic testing, polymerase chain reaction testing, or parasite detection in tissue or fluid specimens. Treatment is recommended for people who are immunosuppressed, pregnant patients with recently acquired infection, and people who are immunocompetent with visceral disease or severe symptoms.

Entities:  

Mesh:

Year:  2021        PMID: 34523888      PMCID: PMC9096899     

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   5.305


  17 in total

1.  Risk factors for Toxoplasma gondii infection in the United States.

Authors:  Jeffrey L Jones; Valerie Dargelas; Jacquelin Roberts; Cindy Press; Jack S Remington; Jose G Montoya
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

Review 2.  Neglected parasitic infections: what every family physician needs to know.

Authors:  Dana Woodhall; Jeffrey L Jones; Paul T Cantey; Patricia P Wilkins; Susan P Montgomery
Journal:  Am Fam Physician       Date:  2014-05-15       Impact factor: 3.292

3.  Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling.

Authors:  D Dunn; M Wallon; F Peyron; E Petersen; C Peckham; R Gilbert
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

Review 4.  Chagas disease.

Authors:  Anis Rassi; Anis Rassi; José Antonio Marin-Neto
Journal:  Lancet       Date:  2010-04-17       Impact factor: 79.321

5.  Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments.

Authors:  Samuel Ong; David A Talan; Gregory J Moran; William Mower; Michael Newdow; Victor C W Tsang; Robert W Pinner
Journal:  Emerg Infect Dis       Date:  2002-06       Impact factor: 6.883

6.  Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.

Authors:  Hector H Garcia; Isidro Gonzales; Andres G Lescano; Javier A Bustos; Mirko Zimic; Diego Escalante; Herbert Saavedra; Martin Gavidia; Lourdes Rodriguez; Enrique Najar; Hugo Umeres; E Javier Pretell
Journal:  Lancet Infect Dis       Date:  2014-07-03       Impact factor: 25.071

Review 7.  Evaluation and treatment of chagas disease in the United States: a systematic review.

Authors:  Caryn Bern; Susan P Montgomery; Barbara L Herwaldt; Anis Rassi; Jose Antonio Marin-Neto; Roberto O Dantas; James H Maguire; Harry Acquatella; Carlos Morillo; Louis V Kirchhoff; Robert H Gilman; Pedro A Reyes; Roberto Salvatella; Anne C Moore
Journal:  JAMA       Date:  2007-11-14       Impact factor: 56.272

8.  An estimate of the burden of Chagas disease in the United States.

Authors:  Caryn Bern; Susan P Montgomery
Journal:  Clin Infect Dis       Date:  2009-09-01       Impact factor: 9.079

9.  Natural History of Treated Subarachnoid Neurocysticercosis.

Authors:  Theodore E Nash; Elise M O'Connell; Dima A Hammoud; Lauren Wetzler; JeanAnne M Ware; Siddhartha Mahanty
Journal:  Am J Trop Med Hyg       Date:  2020-01       Impact factor: 2.345

10.  Deaths from cysticercosis, United States.

Authors:  Frank J Sorvillo; Christopher DeGiorgio; Stephen H Waterman
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.